Completed PHASE4 INTERVENTIONAL 2-arm NCT00545480

SUMMIT Study: A Study of Persistence to Bonviva (Ibandronate) Once Monthly in Women With Post-Menopausal Osteoporosis.

A Randomized, Open-label Study to Investigate the Impact of Bone Marker Feedback on Persistence to Once Monthly Oral Bonviva (Ibandronate) Treatment for Post-menopausal Osteoporosis.

Sponsor: GlaxoSmithKline

Conditions Post Menopausal Osteoporosis

Interventions ibandronate [Bonviva/Boniva]

Updated 7 times since 2017 Last updated: Aug 17, 2015 Started: Jul 31, 2006 Primary completion: Mar 31, 2009 Completion: Mar 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00545480, this PHASE4 trial focuses on Post Menopausal Osteoporosis and remains completed. Sponsored by GlaxoSmithKline, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE4
Sep 2025 — Present [monthly]

Completed PHASE4
Sep 2024 — Sep 2025 [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

GlaxoSmithKline
Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Agen, France , Aix-les-Bains, France , Albert, France , Amboise, France , Amiens, France , Andernos-les-Bains, France , Andrézieux-Bouthéon, France , Angers, France , Angoulême, France , Annecy, France and 158 more locations